We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) entered a definitive agreement with U.S.-based company Elanco Animal Health (ELAN - Free Report) to divest its Animal Health business for $7.6 billion.
Elanco will finance the acquisition with a mix of cash and stock. Bayer will receive $5.32 billion in cash and $2.3 billion in Elanco Animal Health common shares. The transaction is expected to close in mid-2020.
Shares of Bayer have gained 8.1% year to date compared with the industry’s growth of 1.6%.
The sale of the Animal Health business marks the largest transaction in the series of portfolio measures initiated by Bayer in November 2018. The sale enhances the company’s focus as a global leader in life sciences. The company, in November, had also announced the divestitures of its sun-care product, Coppertone, and foot-care brand, Dr. Scholl's, along with the sale of its 60% stake in German site services provider, Currenta.
Bayer’s Animal Health business is a global leader in the animal health segment, with sales of $1.8 billion in fiscal 2018. Meanwhile, from Elanco’s point of view, the deal will be highly complementary. It will create the second-biggest animal health company, with top three positions across a broad range of species and geographies. The acquisition will enable Elanco to increase its portfolio of leading global brands, and bolster its innovation capabilities and R&D pipeline. The deal will also combine Elanco's strong relationship with veterinarians and Bayer's leadership in retail and e-commerce. These will ultimately benefit Elanco’s customers.
We note that Elanco was spun-off from Eli Lilly and Co. (LLY - Free Report) and it started operating as an independent entity from March 2019. We further note that another big-wig Pfizer (PFE - Free Report) had spun-off its animal health business, Zoetis in 2013.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco
Bayer AG (BAYRY - Free Report) entered a definitive agreement with U.S.-based company Elanco Animal Health (ELAN - Free Report) to divest its Animal Health business for $7.6 billion.
Elanco will finance the acquisition with a mix of cash and stock. Bayer will receive $5.32 billion in cash and $2.3 billion in Elanco Animal Health common shares. The transaction is expected to close in mid-2020.
Shares of Bayer have gained 8.1% year to date compared with the industry’s growth of 1.6%.
The sale of the Animal Health business marks the largest transaction in the series of portfolio measures initiated by Bayer in November 2018. The sale enhances the company’s focus as a global leader in life sciences. The company, in November, had also announced the divestitures of its sun-care product, Coppertone, and foot-care brand, Dr. Scholl's, along with the sale of its 60% stake in German site services provider, Currenta.
Bayer’s Animal Health business is a global leader in the animal health segment, with sales of $1.8 billion in fiscal 2018. Meanwhile, from Elanco’s point of view, the deal will be highly complementary. It will create the second-biggest animal health company, with top three positions across a broad range of species and geographies. The acquisition will enable Elanco to increase its portfolio of leading global brands, and bolster its innovation capabilities and R&D pipeline. The deal will also combine Elanco's strong relationship with veterinarians and Bayer's leadership in retail and e-commerce. These will ultimately benefit Elanco’s customers.
We note that Elanco was spun-off from Eli Lilly and Co. (LLY - Free Report) and it started operating as an independent entity from March 2019. We further note that another big-wig Pfizer (PFE - Free Report) had spun-off its animal health business, Zoetis in 2013.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft price | Bayer Aktiengesellschaft Quote
Bayer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>